The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Enhertu Braced for Price Cuts as Chuikyo OKs CEA Results; Evrysdi Not Subject to Scheme
Japan’s all-important reimbursement policy council on March 23 approved the results of cost-effectiveness assessments (CEAs) for Daiichi Sankyo’s cancer drug Enhertu (trastuzumab deruxtecan), putting it in line for a downward price adjustment. Enhertu, an antibody drug conjugate (ADC), joined the…
To read the full story
Related Article
- Enhertu to Get 2.2% Price Cut in July under CEA Scheme
April 13, 2022
- Daiichi Sankyo Missed Goal on CEA Data Submission, but Delay Deemed Reasonable
September 16, 2021
REGULATORY
- Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
- Japan, Spain Move to Deepen Pharmaceutical Regulatory Cooperation
December 23, 2025
- Japan Drops Transitional Plan for PCV20 Routine Shot in Elderly
December 23, 2025
- Tecartus Now in Line for Orphan Status with Japan Panel Nod
December 23, 2025
- LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…